Compare VSME & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSME | ALZN |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.3M |
| IPO Year | 2023 | 2021 |
| Metric | VSME | ALZN |
|---|---|---|
| Price | $1.82 | $2.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 484.6K | 88.3K |
| Earning Date | 04-14-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,483,152.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $1.69 |
| 52 Week High | $64.20 | $10.71 |
| Indicator | VSME | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 52.00 |
| Support Level | $1.63 | $2.01 |
| Resistance Level | $2.00 | $2.54 |
| Average True Range (ATR) | 0.25 | 0.13 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 40.03 | 42.46 |
VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: Creators and Brands. The Value to Creators, that empowers and supports Creators by providing them with production facilities, training, and funding to produce quality content and the Value to Brands, where the company bridges the divide between Brands and Creators by helping Brands reach their target audience effectively by advising on content and budget and recommending specific Creators.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.